<p>諾瓦瓦克斯（NasdaqGS:NVAX）最近報告了 2025 年第一季度的顯著財務好轉，顯示出可觀的收入增長和淨利潤改善。與武田的合作協議的修訂提供了在疫苗開發方面更大的靈活性，而查爾斯·牛頓的新董事會任命增強了公司在醫療保健領域的戰略領導力。在過去一週，諾瓦瓦克斯的股價上漲了 13%，略微超過了整體市場 5% 的漲幅，表明投資者對這些發展的樂觀情緒。這些因素可能進一步推動了股票的上漲，符合積極的市場趨勢。</p>
<p>我們認為諾瓦瓦克斯有 5 個可能的警示信號（其中 2 個比較不愉快），你應該瞭解。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth"/></p>
<p>截至 2025 年 5 月的 NasdaqGS:NVAX 每股收益增長</p>
<p>揭示 16 家在 COVID 後生存並繁榮的公司，它們具備生存特朗普關税的正確要素。</p>
<p>諾瓦瓦克斯最近的組織變動和與武田的合作修訂可能會增強公司的未來收入來源和運營靈活性。在這些公告後，股價上漲 13% 表明投資者信心上升。然而，從長遠來看，考慮到股價變動和股息，公司總回報在過去一年中下降了 48.27%。這一時期突顯了諾瓦瓦克斯面臨的重大波動性和挑戰，強調了持續戰略調整的必要性。</p>
<p>與整體市場上漲 11.9% 和美國生物技術行業在過去一年中下降 14.2% 相比，諾瓦瓦克斯的股票表現顯著不佳。分析師預測，未來三年收入預計將每年下降 31%，而收益預計將每年下降 44.3%。最近的公告可能有助於緩解部分下降，通過潛在擴大市場機會和通過合作伙伴關係增強盈利能力，但對合作夥伴執行的持續依賴仍然是一個主要風險。</p>
<p>分析師設定的目標價為 15.17 美元，顯著高於當前股價 6.42 美元。這意味着如果諾瓦瓦克斯能夠滿足未來預期，潛在增長空間巨大。公司通過合作伙伴關係和成本優化的持續適應是影響其收入和收益增長前景的關鍵因素，使其更接近分析師的估值預期。</p>
<p>通過我們的報告獲取諾瓦瓦克斯的前景和預期表現的見解。</p>
<p><em>這篇文章由 Simply Wall St 撰寫，性質為一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮你的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>如果你想交易諾瓦瓦克斯，請在專業人士信任的最低成本平台 Interactive Brokers 開設賬户。</p>
<p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓你可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
<p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠優於大多數經紀商提供的服務。</p>
<p>贊助內容</p>

諾瓦瓦克斯醫藥

<p>諾瓦瓦克斯（NasdaqGS:NVAX）在 2025 年第一季度報告了顯著的財務好轉，收入增長顯著，淨收入改善。該公司修訂了與武田的合作協議，增強了疫苗開發的靈活性。諾瓦瓦克斯的股價上漲了 13%，超過了大盤 5% 的漲幅，反映了投資者的樂觀情緒。然而，該公司面臨挑戰，包括過去一年總回報下降 48.27% 以及預計收入和盈利下降。分析師設定的目標價為 15.17 美元，表明如果諾瓦瓦克斯能夠滿足預期，仍有增長潛力</p>

<p>Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration agreement with Takeda offers increased flexibility in vaccine development, while the new board appointment of Charles Newton enhances the company's strategic leadership in healthcare. Over the last week, Novavax's shares rose by 13%, slightly exceeding the broader market's 5% increase, indicating investor optimism around these developments. These factors likely reinforced the stock's upward movement, in line with positive market trends.</p>
<div class="lb-trans"><p>諾瓦瓦克斯（NasdaqGS:NVAX）最近報告了 2025 年第一季度的顯著財務好轉，顯示出可觀的收入增長和淨利潤改善。與武田的合作協議的修訂提供了在疫苗開發方面更大的靈活性，而查爾斯·牛頓的新董事會任命增強了公司在醫療保健領域的戰略領導力。在過去一週，諾瓦瓦克斯的股價上漲了 13%，略微超過了整體市場 5% 的漲幅，表明投資者對這些發展的樂觀情緒。這些因素可能進一步推動了股票的上漲，符合積極的市場趨勢。</p>
</div><p>Novavax has 5 possible red flags (and 2 which are a bit unpleasant) we think you should know about.</p>
<div class="lb-trans"><p>我們認為諾瓦瓦克斯有 5 個可能的警示信號（其中 2 個比較不愉快），你應該瞭解。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth" alt="" original-src="https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth"/></p>
<p>NasdaqGS:NVAX Earnings Per Share Growth as at May 2025</p>
<div class="lb-trans"><p>截至 2025 年 5 月的 NasdaqGS:NVAX 每股收益增長</p>
</div><p>Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</p>
<div class="lb-trans"><p>揭示 16 家在 COVID 後生存並繁榮的公司，它們具備生存特朗普關税的正確要素。</p>
</div><p>The recent organizational changes and amendments in Novavax's collaboration with Takeda could potentially bolster the company's future revenue streams and operational flexibility. The increase in share price by 13% following these announcements is indicative of rising investor confidence. However, over the longer term, the company's total return, considering both share price movement and dividends, saw a 48.27% decline over the past year. This period highlights significant volatility and challenges faced by Novavax, underscoring the need for continued strategic adjustments.</p>
<div class="lb-trans"><p>諾瓦瓦克斯最近的組織變動和與武田的合作修訂可能會增強公司的未來收入來源和運營靈活性。在這些公告後，股價上漲 13% 表明投資者信心上升。然而，從長遠來看，考慮到股價變動和股息，公司總回報在過去一年中下降了 48.27%。這一時期突顯了諾瓦瓦克斯面臨的重大波動性和挑戰，強調了持續戰略調整的必要性。</p>
</div><p>Compared to the broader market, which rose 11.9%, and the U.S. Biotechs industry, which experienced a 14.2% decline over the past year, Novavax's shares have underperformed significantly. Analyst forecasts indicate revenue is expected to decline 31% annually over the next three years, with earnings projected to decrease 44.3% annually. The recent announcements might help mitigate some of these declines by potentially expanding market opportunities and enhancing profitability through partnerships, but the ongoing dependency on partner execution remains a major risk.</p>
<div class="lb-trans"><p>與整體市場上漲 11.9% 和美國生物技術行業在過去一年中下降 14.2% 相比，諾瓦瓦克斯的股票表現顯著不佳。分析師預測，未來三年收入預計將每年下降 31%，而收益預計將每年下降 44.3%。最近的公告可能有助於緩解部分下降，通過潛在擴大市場機會和通過合作伙伴關係增強盈利能力，但對合作夥伴執行的持續依賴仍然是一個主要風險。</p>
</div><p>The price target set by analysts is US$15.17, notably higher than the current share price of US$6.42. This implies substantial growth potential if Novavax can meet future expectations. The company's continued adaptation through partnerships and cost optimization efforts are critical elements that could influence its revenue and earnings growth perspectives, moving closer to the analysts' valuation expectations.</p>
<div class="lb-trans"><p>分析師設定的目標價為 15.17 美元，顯著高於當前股價 6.42 美元。這意味着如果諾瓦瓦克斯能夠滿足未來預期，潛在增長空間巨大。公司通過合作伙伴關係和成本優化的持續適應是影響其收入和收益增長前景的關鍵因素，使其更接近分析師的估值預期。</p>
</div><p>Gain insights into Novavax's outlook and expected performance with our report on the company's earnings estimates.</p>
<div class="lb-trans"><p>通過我們的報告獲取諾瓦瓦克斯的前景和預期表現的見解。</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，性質為一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮你的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>If you're looking to trade Novavax, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果你想交易諾瓦瓦克斯，請在專業人士信任的最低成本平台 Interactive Brokers 開設賬户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓你可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠優於大多數經紀商提供的服務。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>贊助內容</p>
</div>

諾瓦瓦克斯醫藥（NasdaqGS:NVAX）公佈 2025 年第一季度財務狀況好轉